A novel antifibrotic mechanism of nintedanib and pirfenidone inhibition of collagen fibril assembly

American Journal of Respiratory Cell and Molecular Biology

Volumn 57, Issue 1, 2017, Pages 77-90

  Knuppel, Larissa ^a   Ishikawa, Yoshihiro ^b,c   Aichler, Michaela ^d   Heinzelmann, Katharina ^a   Hatz, Rudolf ^e,f   Behr, Jurgen ^e,f   Walch, Axel ^d   Bachinger, Hans Peter ^b,c   Eickelberg, Oliver ^a,g   Staab Weijnitz, Claudia A ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c SHRINERS HOSPITAL FOR CHILDREN   (United States)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f ASKLEPIOS FACHKLINIKEN MÜNCHEN GAUTING   (Germany)

^g UNIVERSITY OF COLORADO   (United States)

Author keywords

Extracellular matrix; Idiopathic pulmonary fibrosis; Nintedanib; Pirfenidone

Indexed keywords

CELL PROTEIN; CHAPERONE; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGEN TYPE 5; FIBRONECTIN; FIBRONECTIN 1; FKBP10 PROTEIN; HEAT SHOCK PROTEIN 47; NINTEDANIB; PIRFENIDONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; FIBRILLAR COLLAGEN; FK 506 BINDING PROTEIN; FKBP10 PROTEIN, HUMAN; INDOLE DERIVATIVE; PYRIDONE DERIVATIVE; SCLEROPROTEIN; SERPINH1 PROTEIN, HUMAN;

ARTICLE; CELL MATURATION; COLLAGEN FIBRIL; COLLAGEN SYNTHESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; EFFECTIVE CONCENTRATION; EXTRACELLULAR MATRIX; FIBROBLAST CULTURE; FIBROSING ALVEOLITIS; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; KINETICS; LUNG FIBROBLAST; PHOTON CORRELATION SPECTROSCOPY; POLYMERASE CHAIN REACTION; PRIMARY CELL CULTURE; PROTEIN ASSEMBLY; PROTEIN PROCESSING; PROTEIN SECRETION; QUANTITATIVE ANALYSIS; SCANNING ELECTRON MICROSCOPY; WESTERN BLOTTING; DRUG EFFECTS; FIBROBLAST; GENETIC TRANSCRIPTION; GENETICS; IDIOPATHIC PULMONARY FIBROSIS; LUNG; METABOLISM; PATHOLOGY;

COLLAGEN TYPE I; DOWN-REGULATION; EXTRACELLULAR MATRIX PROTEINS; FIBRILLAR COLLAGENS; FIBROBLASTS; HSP47 HEAT-SHOCK PROTEINS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; LUNG; PROTEIN PROCESSING, POST-TRANSLATIONAL; PYRIDONES; TACROLIMUS BINDING PROTEINS; TRANSCRIPTION, GENETIC;

EID: 85021684126     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2016-0217OC     Document Type: Article

References (47)

1. Kim DS, Collard HR, King TE Jr. Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc 2006;3: 285-292
2. Coward WR, Saini G, Jenkins G. The pathogenesis of idiopathic pulmonary fibrosis. Ther Adv Respir Dis 2010;4:367-388
3. Rock JR, Barkauskas CE, Cronce MJ, Xue Y, Harris JR, Liang J, Noble PW, Hogan BL. Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. Proc Natl Acad Sci USA 2011;108:E1475-E1483
4. Fernandez IE, Eickelberg O. The impact of TGF-b on lung fibrosis: from targeting to biomarkers. Proc Am Thorac Soc 2012;9:111-116
5. Wollin L, Wex E, Pautsch A, Schnapp G, Hostettler KE, Stowasser S, Kolb M. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J 2015;45:1434-1445
6. Decaris ML, Gatmaitan M, FlorCruz S, Luo F, Li K, Holmes WE, Hellerstein MK, Turner SM, Emson CL. Proteomic analysis of altered extracellular matrix turnover in bleomycin-induced pulmonary fibrosis. Mol Cell Proteomics 2014;13:1741-1752
7. Schiller HB, Fernandez IE, Burgstaller G, Schaab C, Scheltema RA, Schwarzmayr T, Strom TM, Eickelberg O, Mann M. Time-and compartment-resolved proteome profiling of the extracellular niche in lung injury and repair. Mol Syst Biol 2015;11:819
8. Ishikawa Y, Bachinger HP. A molecular ensemble in the rER for procollagen maturation. Biochim Biophys Acta 2013;1833: 2479-2491
9. Ishikawa Y, Boudko S, Bachinger HP. Ziploc-ing the structure: triple helix formation is coordinated by rough endoplasmic reticulum resident PPIases. Biochim Biophys Acta 2015;1850:1983-1993
10. Staab-Weijnitz CA, Fernandez IE, Knuppel L, Maul J, Heinzelmann K, Juan-Guardela BM, Hennen E, Preissler G, Winter H, Neurohr C, et al. FK506-binding protein 10, α potential novel drug target for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2015;192: 455-467
11. Razzaque MS, Nazneen A, Taguchi T. Immunolocalization of collagen and collagen-binding heat shock protein 47 in fibrotic lung diseases. Mod Pathol 1998;11:1183-1188
12. Ishida Y, Kubota H, Yamamoto A, Kitamura A, Bachinger HP, Nagata K. Type I collagen in Hsp47-null cells is aggregated in endoplasmic reticulum and deficient in N-propeptide processing and fibrillogenesis. Mol Biol Cell 2006;17:2346-2355
13. Hudson DM, Eyre DR. Collagen prolyl 3-hydroxylation: α major role for a minor post-translational modification? Connect Tissue Res 2013; 54:245-251
14. Weis MA, Hudson DM, Kim L, Scott M, Wu JJ, Eyre DR. Location of 3-hydroxyproline residues in collagen types I, II, III, and V/XI implies a role in fibril supramolecular assembly. J Biol Chem 2010;285: 2580-2590
15. Pokidysheva E, Zientek KD, Ishikawa Y, Mizuno K, Vranka JA, Montgomery NT, Keene DR, Kawaguchi T, Okuyama K, Bachinger HP. Posttranslational modifications in type I collagen from different tissues extracted from wild type and prolyl 3-hydroxylase 1 null mice. J Biol Chem 2013;288:24742-24752
16. Blackwell TS, Tager AM, Borok Z, Moore BB, Schwartz DA, Anstrom KJ, Bar-Joseph Z, Bitterman P, Blackburn MR, Bradford W, et al. Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report. Am J Respir Crit Care Med 2014;189:214-222
17. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, et al.; INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2071-2082
18. Datta A, Scotton CJ, Chambers RC. Novel therapeutic approaches for pulmonary fibrosis. Br J Pharmacol 2011;163:141-172
19. Schaefer CJ, Ruhrmund DW, Pan L, Seiwert SD, Kossen K. Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev 2011;20:85-97
20. Chambers RC, Mercer PF. Mechanisms of alveolar epithelial injury, repair, and fibrosis. Ann Am Thorac Soc 2015;12:S16-S20
21. Hisatomi K, Mukae H, Sakamoto N, Ishimatsu Y, Kakugawa T, Hara S, Fujita H, Nakamichi S, Oku H, Urata Y, et al. Pirfenidone inhibits TGF-b1-induced over-expression of collagen type I and heat shock protein 47 in A549 cells. BMC Pulm Med 2012;12:24
22. Di Sario A, Bendia E, Svegliati Baroni G, Ridolfi F, Casini A, Ceni E, Saccomanno S, Marzioni M, Trozzi L, Sterpetti P, et al. Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production. J Hepatol 2002;37:584-591
23. Huang J, Beyer C, Palumbo-Zerr K, Zhang Y, Ramming A, Distler A, Gelse K, Distler O, Schett G, Wollin L, et al. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis. Ann Rheum Dis 2016;75:883-890
24. Rangarajan S, Kurundkar A, Kurundkar D, Bernard K, Sanders YY, Ding Q, Antony VB, Zhang J, Zmijewski J, Thannickal VJ. Novel mechanisms for the anti-fibrotic action of nintedanib. Am J Respir Cell Mol Biol 2016;54:51-59
25. Hostettler KE, Zhong J, Papakonstantinou E, Karakiulakis G, Tamm M, Seidel P, Sun Q, Mandal J, Lardinois D, Lambers C, et al. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis. Respir Res 2014;15:157
26. Nakayama S, Mukae H, Sakamoto N, Kakugawa T, Yoshioka S, Soda H, Oku H, Urata Y, Kondo T, Kubota H, et al. Pirfenidone inhibits the expression of HSP47 in TGF-b1-stimulated human lung fibroblasts. Life Sci 2008;82:210-217
27. Ishikawa Y, Bachinger HP. A substrate preference for the rough endoplasmic reticulum resident protein FKBP22 during collagen biosynthesis. J Biol Chem 2014;289:18189-18201
28. Shin JM, Park JH, Park IH, Lee HM. Pirfenidone inhibits transforming growth factor b1-induced extracellular matrix production in nasal polyp-derived fibroblasts. Am J Rhinol Allergy 2015;29:408-413
29. Hashizume H, Hitomi J, Ushiki T. Growth of collagen fibrils produced by human osteosarcoma cells: high-resolution scanning electron microscopy. Arch Histol Cytol 1999;62:327-335
30. Williams BR, Gelman RA, Poppke DC, Piez KA. Collagen fibril formation. Optimal in vitro conditions and preliminary kinetic results. J Biol Chem 1978;253:6578-6585
31. Kadler KE, Holmes DF, Trotter JA, Chapman JA. Collagen fibril formation. Biochem J 1996;316:1-11
32. Lin X, Yu M, Wu K, Yuan H, Zhong H. Effects of pirfenidone on proliferation, migration, and collagen contraction of human Tenon's fibroblasts in vitro. Invest Ophthalmol Vis Sci 2009;50:3763-3770
33. Pierce GF, Mustoe TA, Altrock BW, Deuel TF, Thomason A. Role of platelet-derived growth factor in wound healing. J Cell Biochem 1991;45:319-326
34. Heinzelmann K, NoskovičováN, Merl-Pham J, Preissler G, Winter H, Lindner M, Hatz R, Hauck SM, Behr J, Eickelberg O. Surface proteome analysis identifies platelet derived growth factor receptor-A as α critical mediator of transforming growth factor-b-induced collagen secretion. Int J Biochem Cell Biol 2016;74:44-59
35. Tourkina E, Richard M, Gooz P, Bonner M, Pannu J, Harley R, Bernatchez PN, Sessa WC, Silver RM, Hoffman S. Antifibrotic properties of caveolin-1 scaffolding domain in vitro and in vivo. Am J Physiol Lung Cell Mol Physiol 2008;294:L843-L861
36. Wollin L, Schuett J, Ostermann A. The effect of nintedanib compared to pirfenidone on serum-stimulated proliferation of human primary lung fibroblasts at clinically relevant concentrations. Am J Respir Crit Care Med 2015;191:A4940
37. Parra ER, Teodoro WR, Velosa AP, de Oliveira CC, Yoshinari NH, Capelozzi VL. Interstitial and vascular type V collagen morphologic disorganization in usual interstitial pneumonia. J Histochem Cytochem 2006;54:1315-1325
38. Vittal R, Mickler EA, Fisher AJ, Zhang C, Rothhaar K, Gu H, Brown KM, Emtiazdjoo A, Lott JM, Frye SB, et al. Type V collagen induced tolerance suppresses collagen deposition, TGF-b and associated transcripts in pulmonary fibrosis. PLoS One 2013;8:e76451
39. Wenstrup RJ, Florer JB, Brunskill EW, Bell SM, Chervoneva I, Birk DE. Type V collagen controls the initiation of collagen fibril assembly. J Biol Chem 2004;279:53331-53337
40. Dancer RC, Wood AM, Thickett DR. Metalloproteinases in idiopathic pulmonary fibrosis. Eur Respir J 2011;38:1461-1467
41. Lindert U, Weis MA, Rai J, Seeliger F, Hausser I, Leeb T, Eyre D, Rohrbach M, Giunta C. Molecular Consequences of the SERPINH1/HSP47 mutation in the Dachshund natural model of osteogenesis imperfecta. J Biol Chem 2015;290:17679-17689
42. Barnes AM, Cabral WA, Weis M, Makareeva E, Mertz EL, Leikin S, Eyre D, Trujillo C, Marini JC. Absence of FKBP10 in recessive type XI osteogenesis imperfecta leads to diminished collagen cross-linking and reduced collagen deposition in extracellular matrix. Hum Mutat 2012; 33:1589-1598
43. Parker MW, Rossi D, Peterson M, Smith K, Sikstrom K, White ES, Connett JE, Henke CA, Larsson O, Bitterman PB. Fibrotic extracellular matrix activates α profibrotic positive feedback loop. J Clin Invest 2014;124: 1622-1635
44. Chung HJ, Steplewski A, Chung KY, Uitto J, Fertala A. Collagen fibril formation. A new target to limit fibrosis. J Biol Chem 2008;283:25879-25886
45. Cox TR, Bird D, Baker AM, Barker HE, Ho MW, Lang G, Erler JT. LOXmediated collagen crosslinking is responsible for fibrosis-enhanced metastasis. Cancer Res 2013;73:1721-1732
46. Gilead. Gilead terminates phase 2 study of simtuzumab in patients with idiopathic pulmonary fibrosis. Foster City, CA: Gilead Sciences, Inc.; January 5, 2016 [accessed 2016 Jul 12]. Available from: http:// www.gilead.com/news/press-releases/2016/1/gilead-terminatesphase-2-study-of-simtuzumab-in-patients-with-idiopathicpulmonary-fibrosis
47. Lehtonen ST, Veijola A, Karvonen H, Lappi-Blanco E, Sormunen R, Korpela S, Zagai U, Skold MC, Kaarteenaho R. Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis. Respir Res 2016;17:14